[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562898":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":11,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic Group","EXPERIMENTAL",null,[13],"Dietary Supplement: De Simone formulation probiotic",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Group","PLACEBO_COMPARATOR",[18],"Dietary Supplement: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DIETARY_SUPPLEMENT","De Simone formulation probiotic","Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","Subjects will be given a placebo for 21-24 days",[15],[30],{"name":31,"affiliation":5,"role":32},"Michael Camilleri, MD, DSc","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"John Damianos, MD","CONTACT","5072842511","damianos.john@mayo.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-92.4699,44.02163,{"lat":52,"lon":51},[55],{"name":56,"role":32,"phone":11,"phoneExt":11,"email":11},"Michael Camilleri",{"type":32,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Michael Camilleri, MD","Principal Investigator","100562898","probiotic-in-patients-with-bile-acid-malabsorptiondiarrhea-100562898",false,"NCT06609148","Probiotic in Patients With Bile Acid Malabsorption\u002FDiarrhea","Randomized, Double-Blind, Placebo-Controlled Trial of De Simone Formulation Probiotic in Patients With Bile Acid Malabsorption\u002FDiarrhea Unassociated With Ileal Resection","Inclusion criteria:\n\n* Prior diagnosis of bile acid malabsorption documented in the medical history based on\n\n  * either serum C4 \\>52.5ng\u002FmL, or\n  * fecal 48h total BA excretion \\>2337 μmol\u002F48h, or\n  * primary BA \\>5% 48h stool collection or \\>10% in single stool sample.\n* 7-day stool dairy with an average stool consistency based on the Bristol Stool Form Scale, BSFS, with a grade greater than 5. Note: If Inclusion criteria 3 is not met, participants may choose to have their blood drawn clinically to further determine eligibility.\n* For women of childbearing potential\n\n  * A negative urine pregnancy test prior to dispensing the study product\n  * Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study:\n\n    * Surgical sterilization\n    * Hormonal contraception (implantable, patch, oral, intra-muscular)\n    * Intra-uterine device\n    * Double barrier method (diaphragm plus condom)\n    * At the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance\n\nExclusion criteria:\n\n* Use of oral antibiotics and probiotics within the last 4 weeks.\n* Pregnancy or lactation.\n* Concomitant use of bile acid sequestrants, must stop 10 days before starting 7-day stool dairy and for the duration of the study.\n* History of ileal resection.\n* Diabetes mellitus (type 1)\n* BMI ≥ 40 kg\u002Fm\\^2\n* Diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac diseases or gastrointestinal infection in the prior 4 weeks\n* Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments","ALL","18 Years",{"count":70,"type":71},24,"ESTIMATED","INTERVENTIONAL",[74],"NA","The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.",[77,78],"Bile Acid Malabsorption","Bile Acid Diarrhea","2026-05-08",{"date":81,"type":82},"2026-05-11","ACTUAL",{"date":84,"type":82},"2025-01-02",{"date":86,"type":71},"2026-06-30",{"name":5,"class":6},1]